These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 9533981)
81. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group. Lalezari J J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):195-7. PubMed ID: 9768631 [No Abstract] [Full Text] [Related]
82. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Berginc K; Trontelj J; Kristl A Drug Metab Pharmacokinet; 2010; 25(3):307-13. PubMed ID: 20610890 [TBL] [Abstract][Full Text] [Related]
83. HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? Maksimovic-Ivanic D; Fagone P; McCubrey J; Bendtzen K; Mijatovic S; Nicoletti F Int J Cancer; 2017 Apr; 140(8):1713-1726. PubMed ID: 27870005 [TBL] [Abstract][Full Text] [Related]
84. [Drug interactions with antiretroviral agents]. Furlan V; Taburet AM Therapie; 2001; 56(3):267-71. PubMed ID: 11475806 [TBL] [Abstract][Full Text] [Related]
85. Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro. Lazdins JK; Bold G; Capraro HG; Cozens R; Fässler A; Flesch G; Klimkait T; Lang M; Mestan J; Poncioni B; Rösel J; Stover D; Tintelnot-Blomley M; Walker MR; Woods-Cook K Schweiz Med Wochenschr; 1996 Oct; 126(43):1849-51. PubMed ID: 8916294 [TBL] [Abstract][Full Text] [Related]
86. Examining pharmacodynamic and pharmacokinetic properties of eleven analogues of saquinavir for HIV protease inhibition. Jayaswal A; Mishra H; Mishra A; Shah K Arch Virol; 2019 Apr; 164(4):949-960. PubMed ID: 30680529 [TBL] [Abstract][Full Text] [Related]
87. Gynaecomastia associated with saquinavir therapy. Donovan B; Bodsworth NJ; Mulhall BP; Allen D Int J STD AIDS; 1999 Jan; 10(1):49-50. PubMed ID: 10215131 [No Abstract] [Full Text] [Related]
88. Food consumption, cytochrome P450 3A4 (CYP3A4) presystemic inhibitors, and bioavailability of saquinavir. Amariles P Farm Hosp; 2007; 31(1):68-70. PubMed ID: 17439316 [No Abstract] [Full Text] [Related]
90. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection. Hoetelmans RM; van Essenberg M; Meenhorst PL; Mulder JW; Beijnen JH J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):235-41. PubMed ID: 9367213 [TBL] [Abstract][Full Text] [Related]
91. Acute paranoid reaction to saquinavir. Finlayson JA; Laing RB Am J Health Syst Pharm; 1998 Oct; 55(19):2016-7. PubMed ID: 9784791 [No Abstract] [Full Text] [Related]
92. Saquinavir: From HIV to COVID-19 and Cancer Treatment. Pereira M; Vale N Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883499 [TBL] [Abstract][Full Text] [Related]
93. [New strategies for antiretroviral treatment in HIV infected patients]. Garrait V; Molina JM Pathol Biol (Paris); 2001 Feb; 49(1):67-71. PubMed ID: 11265226 [TBL] [Abstract][Full Text] [Related]
94. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Gong Y; Haque S; Chowdhury P; Cory TJ; Kodidela S; Yallapu MM; Norwood JM; Kumar S Expert Opin Drug Metab Toxicol; 2019 May; 15(5):417-427. PubMed ID: 30951643 [TBL] [Abstract][Full Text] [Related]
95. Overview of protease inhibitors. Pakyz A; Israel D J Am Pharm Assoc (Wash); 1997; NS37(5):543-51. PubMed ID: 9479406 [TBL] [Abstract][Full Text] [Related]
96. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Becker SL Expert Opin Investig Drugs; 2003 Mar; 12(3):401-12. PubMed ID: 12605563 [TBL] [Abstract][Full Text] [Related]